Document is current
Any future updates will be listed below
-
Authors
Zilbauer, Matthias http://orcid.org/0000-0002-7272-0547
James, Kylie R. http://orcid.org/0000-0002-7107-0650
Kaur, Mandeep http://orcid.org/0000-0002-9757-4048
Pott, Sebastian http://orcid.org/0000-0002-4118-6150
Li, Zhixin http://orcid.org/0000-0001-9962-3942
Burger, Albert
Thiagarajah, Jay R. http://orcid.org/0000-0002-1437-325X
Burclaff, Joseph http://orcid.org/0000-0002-0325-5039
Jahnsen, Frode L.
Perrone, Francesca
Ross, Alexander D.
Matteoli, Gianluca http://orcid.org/0000-0002-2902-4976
Stakenborg, Nathalie http://orcid.org/0000-0002-6229-0045
Sujino, Tomohisa http://orcid.org/0000-0003-0699-6577
Moor, Andreas http://orcid.org/0000-0001-8715-8449
Bartolome-Casado, Raquel http://orcid.org/0000-0002-8966-9047
Bækkevold, Espen S.
Zhou, Ran http://orcid.org/0000-0002-0562-4483
Xie, Bingqing
Lau, Ken S. http://orcid.org/0000-0001-8438-0319
Din, Shahida http://orcid.org/0000-0003-2855-3400
Magness, Scott T.
Yao, Qiuming
Beyaz, Semir
Arends, Mark http://orcid.org/0000-0002-6826-8770
Denadai-Souza, Alexandre http://orcid.org/0000-0003-0385-1321
Coburn, Lori A. http://orcid.org/0000-0003-3249-9806
Gaublomme, Jellert T.
Baldock, Richard http://orcid.org/0000-0003-0332-6877
Papatheodorou, Irene http://orcid.org/0000-0001-7270-5470
Ordovas-Montanes, Jose http://orcid.org/0000-0001-5444-5601
Boeckxstaens, Guy http://orcid.org/0000-0001-8267-5797
Hupalowska, Anna
Teichmann, Sarah A. http://orcid.org/0000-0002-6294-6366
Regev, Aviv
Xavier, Ramnik J. http://orcid.org/0000-0002-5630-5167
Simmons, Alison
Snyder, Michael P. http://orcid.org/0000-0003-0784-7987
Wilson, Keith T. http://orcid.org/0000-0003-4421-1830
,
,
- License Information
-
More Information
Article History
Accepted: 14 April 2023
First Online: 31 May 2023
Competing interests
: In the past 3 years, S.A.T. has consulted or been a member of scientific advisory boards at Roche, Genentech, Biogen, GlaxoSmithKline, Qiagen and ForeSite Labs and is an equity holder of Transition Bio. G.M. has received grant funding from Boehringer Ingelheim. A. Regev is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was a SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. Since 1 August 2020, A. Regev has been an employee of Genentech and has equity in Roche. A. Regev is an inventor on patents and patent applications filed at the Broad Institute related to single-cell genomics. The remaining authors declare no competing interests.
